Galectin Therapeutics Inc.
GALT
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with faā¦ read more
Healthcare
Biotechnology
23 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.52
Price+0.29%
$0.01
1Y
Price
Market Cap
$231.816m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$26.251m
+14.9%
1y CAGR+11.6%
3y CAGR+7.2%
5y CAGREPS
-$0.41
+14.6%
1y CAGR+16.2%
3y CAGR+8.7%
5y CAGRBook Value
-$130.237m
$15.759m
Assets$145.996m
Liabilities$135.716m
DebtDebt to Assets
861.2%
-7.3x
Debt to EBITDAFree Cash Flow
-$20.052m
+16.0%
1y CAGR+10.7%
3y CAGR+6.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company